Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from RedHill Biopharma ( (RDHL) ) is now available.
On July 1, 2025, RedHill Biopharma announced the initiation of patient recruitment for a Phase 2 study evaluating the combination of opaganib and darolutamide in men with metastatic castrate-resistant prostate cancer (mCRPC). Sponsored by ANZUP and supported by Bayer and Ramsay Hospital Research Foundation, the study aims to assess the efficacy of this combination in overcoming resistance to standard androgen receptor pathway inhibition treatments. The study will recruit 60 participants across Australia and New Zealand, utilizing a precision medicine approach with the PCPro lipid biomarker test to identify patients most likely to benefit. This marks a significant step in RedHill’s oncology development, potentially enhancing its market position in the prostate cancer treatment landscape.
Spark’s Take on RDHL Stock
According to Spark, TipRanks’ AI Analyst, RDHL is a Neutral.
The most significant risk comes from financial performance, with negative margins and cash flow problems posing major challenges. Technical analysis supports a bearish trend. Lack of valuation data and earnings call information limits further insights.
To see Spark’s full report on RDHL stock, click here.
More about RedHill Biopharma
RedHill Biopharma Ltd. is a specialty biopharmaceutical company based in Tel Aviv, Israel, and Raleigh, NC. The company focuses on developing and commercializing proprietary drugs for the treatment of gastrointestinal diseases, infectious diseases, and cancer. RedHill’s pipeline includes investigational drugs for various indications, including oncology and pandemic preparedness.
Average Trading Volume: 222,826
Technical Sentiment Signal: Sell
Current Market Cap: $4.26M
For detailed information about RDHL stock, go to TipRanks’ Stock Analysis page.